JP2018500878A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500878A5
JP2018500878A5 JP2017523804A JP2017523804A JP2018500878A5 JP 2018500878 A5 JP2018500878 A5 JP 2018500878A5 JP 2017523804 A JP2017523804 A JP 2017523804A JP 2017523804 A JP2017523804 A JP 2017523804A JP 2018500878 A5 JP2018500878 A5 JP 2018500878A5
Authority
JP
Japan
Prior art keywords
glycoprotein
dengue virus
antibody
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017523804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500878A (ja
JP6671364B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/058610 external-priority patent/WO2016070178A1/en
Publication of JP2018500878A publication Critical patent/JP2018500878A/ja
Publication of JP2018500878A5 publication Critical patent/JP2018500878A5/ja
Application granted granted Critical
Publication of JP6671364B2 publication Critical patent/JP6671364B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017523804A 2014-11-02 2015-11-02 ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物 Expired - Fee Related JP6671364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074053P 2014-11-02 2014-11-02
US62/074,053 2014-11-02
PCT/US2015/058610 WO2016070178A1 (en) 2014-11-02 2015-11-02 Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development

Publications (3)

Publication Number Publication Date
JP2018500878A JP2018500878A (ja) 2018-01-18
JP2018500878A5 true JP2018500878A5 (https=) 2018-12-13
JP6671364B2 JP6671364B2 (ja) 2020-03-25

Family

ID=55858450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523804A Expired - Fee Related JP6671364B2 (ja) 2014-11-02 2015-11-02 ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物

Country Status (12)

Country Link
US (2) US10398768B2 (https=)
EP (1) EP3212672A4 (https=)
JP (1) JP6671364B2 (https=)
KR (1) KR20170075775A (https=)
CN (1) CN107207619A (https=)
AU (1) AU2015338859A1 (https=)
BR (1) BR112017008952A2 (https=)
CA (1) CA2966198A1 (https=)
MX (1) MX2017005524A (https=)
MY (1) MY179251A (https=)
SG (1) SG11201703366RA (https=)
WO (1) WO2016070178A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026845A1 (en) * 2016-08-01 2018-02-08 Inbios International, Inc. Immunoassay methods and compositions for detecting infection involving use of test antigens as cross-reactive control antigens
CN106632620B (zh) * 2016-11-29 2019-08-23 菲鹏生物股份有限公司 登革病毒重组抗原及其制备方法和应用
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
CN110568190A (zh) * 2019-08-30 2019-12-13 深圳国际旅行卫生保健中心 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法
WO2021102363A1 (en) * 2019-11-20 2021-05-27 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
US20250188130A1 (en) * 2022-03-17 2025-06-12 The University Of North Carolina At Chapel Hill Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same
CN116716322B (zh) * 2023-05-12 2024-05-31 中山大学 一种denv-3全长感染性克隆及其构建方法与应用
WO2024238948A2 (en) * 2023-05-17 2024-11-21 University Of Iowa Research Foundation Dengue virus serotype-specific modulation of t cell responses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
PL2589602T3 (pl) * 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi
US9821050B2 (en) * 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
ES2745431T3 (es) * 2013-06-26 2020-03-02 Univ North Carolina Chapel Hill Composiciones para vacunas contra el virus del dengue y su uso

Similar Documents

Publication Publication Date Title
JP2018500878A5 (https=)
Fougeroux et al. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
Sun et al. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice
CY1124202T1 (el) Εμβολια ανασυνδυασμενου zika
Pimentel et al. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine
Malhi et al. Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge
Krammer et al. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin
Park et al. Analyzing immune responses to varied mRNA and protein vaccine sequences
Tamminen et al. A comparison of immunogenicity of norovirus GII‐4 virus‐like particles and P‐particles
JP2015524422A5 (https=)
Carignan et al. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
RU2015155821A (ru) Вакцины против малярии
ZA202104213B (en) Antibodies that neutralize hepatitis b virus and uses thereof
NO20090178L (no) Vaksiner for malaria
RU2019107976A (ru) Композиция вакцины
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
Song et al. Plant‐based, adjuvant‐free, potent multivalent vaccines for avian influenza virus via Lactococcus surface display
JP2016504993A5 (https=)
RU2021109510A (ru) Вакцинация с использованием альфа 3 домена mica/b для лечения рака
Davenport et al. Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
RU2016133598A (ru) Композиция микобактериального антигена
Abente et al. Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs
Moreno et al. Rabbit hemorrhagic disease virus capsid, a versatile platform for foreign B-cell epitope display inducing protective humoral immune responses
JP2016528176A5 (https=)